Posts fully diluted earnings per share of $0.08 for fourth quarter
of 2009; $0.09 excluding items Generates over $16.5 million in
operating cash flow for 2009 ATLANTA, Feb. 18
/PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE:CRY), an implantable
biological medical device and cardiovascular tissue processing
company, announced today that revenues for the fourth quarter of
2009 increased 12 percent to a quarterly record of $28.6 million
compared to $25.5 million for the fourth quarter of 2008. This was
the 12th consecutive quarter of profitability for the Company.
"CryoLife is continuing to thrive in very demanding economic
conditions. In addition to reporting record revenues and continued,
consistent profitability, our ability to significantly increase our
cash balances over the past year is a very encouraging sign of the
health of our business. Looking ahead, we expect to achieve record
revenues and operating earnings in 2010 by continuing to execute on
our strategy and invest in our growth," stated Steven G. Anderson,
president and chief executive officer. Net income for the fourth
quarter of 2009 was $2.4 million, or $0.08 per basic and fully
diluted common share, compared to $21.7 million, or $0.78 per basic
and $0.76 per fully diluted common share for the fourth quarter of
2008. The Company's effective income tax rate was 36 percent for
the fourth quarter of 2009, compared to a tax benefit for the
fourth quarter of 2008. The Company had a tax benefit in 2008 due
to the reversal of the Company's valuation allowance on its
deferred tax assets during 2008. If the Company had recorded 2008
income taxes at a comparable 36 percent effective tax rate, net
income for the fourth quarter of 2008 would have been $1.7 million
and fully diluted earnings per share would have been $0.06. The
Company recorded a pretax charge of approximately $377,000 in the
fourth quarter of 2009 in connection with a reduction in workforce,
which resulted from several process improvements and expense
control and cost cutting initiatives that the Company implemented
during the fourth quarter of 2009. Excluding these charges, net
income for the fourth quarter of 2009 would have been $2.6 million,
or $0.09 per fully diluted common share. Revenues for the full year
of 2009 increased 6 percent to a record $111.7 million compared to
$105.1 million for the full year of 2008. Net income for the full
year of 2009 was $8.7 million, or $0.31 per basic and fully diluted
common share, compared to $32.0 million, or $1.15 per basic and
$1.13 per fully diluted common share for the full year of 2008. The
Company's effective income tax rate was 40 percent for the full
year of 2009, compared to a tax benefit for the full year of 2008.
If the Company had recorded 2008 income taxes at a comparable 40
percent effective tax rate, net income for the full year of 2008
would have been $8.1 million and fully diluted earnings per share
would have been $0.29. Excluding pretax charges of $377,000 in the
fourth quarter of 2009 as mentioned above, net income for the full
year of 2009 would have been $8.9 million, or $0.32 per fully
diluted common share. Preservation service revenues for the fourth
quarter of 2009 increased 12 percent to $13.8 million compared to
$12.3 million for the fourth quarter of 2008. The increase in
preservation service revenues was primarily due to increased
shipments of cardiac and vascular tissues for the fourth quarter of
2009 compared to the fourth quarter of 2008. Preservation service
revenues for the full year of 2009 increased 5 percent to $56.5
million compared to $53.7 million for the full year of 2008.
Excluding orthopaedic tissue processing revenues of $181,000 and
$725,000 for the full year of 2009 and 2008, respectively,
preservation service revenues increased 6 percent to $56.3 million
for the full year of 2009 compared to $52.9 million for the full
year of 2008. The increase in preservation service revenues was
primarily due to increased revenues from vascular tissue for the
full year of 2009 compared to the full year of 2008. Revenues from
the distribution of CryoValve® SG pulmonary heart valves
("CryoValve SGPV") and CryoPatch® SG pulmonary cardiac patches
("CryoPatch SG") increased to $2.2 million for the fourth quarter
of 2009 from $1.7 million for the fourth quarter of 2008,
representing 33 percent of the Company's cardiac tissue processing
revenues for the fourth quarter of 2009. Revenues from the
distribution of CryoValve SGPV and CryoPatch SG increased to $6.8
million for the full year of 2009 from $5.1 million for the full
year of 2008, representing 26 percent of the Company's cardiac
tissue processing revenues for the full year of 2009. Product
revenues, which consist primarily of sales of BioGlue® Surgical
Adhesive and HemoStase®, were $14.5 million for the fourth quarter
of 2009 compared to $13.0 million for the fourth quarter of 2008,
an increase of 12 percent. Product revenues were $54.2 million for
the full year of 2009 compared to $50.5 million for the full year
of 2008, an increase of 7 percent. The increase year over year
primarily reflects the growing usage of HemoStase in cardiac and
vascular surgical indications in the U.S., and cardiac, vascular
and general surgery indications in many markets outside of the U.S.
Total preservation services and product gross margins were 61
percent and 64 percent for the fourth quarters of 2009 and 2008,
respectively. Total preservation services and product gross margins
were 62 percent and 64 percent for the full year of 2009 and 2008,
respectively. Preservation services gross margins were 39 percent
and 45 percent for the fourth quarters of 2009 and 2008,
respectively. Preservation services gross margins were 42 percent
and 46 percent for the full year of 2009 and 2008, respectively.
Product gross margins were 82 percent for each of the fourth
quarters of 2009 and 2008. Product gross margins were 83 percent
and 84 percent for the full year of 2009 and 2008, respectively.
General, administrative, and marketing expenses for the fourth
quarter of 2009 were $12.6 million compared to $12.3 million for
the fourth quarter of 2008. General, administrative, and marketing
expenses for the full year of 2009 were $50.0 million compared to
$48.8 million for the full year of 2008. These expenses included
personnel costs, advertising, physician education and training, and
promotional materials to support current revenue growth and the
Company's efforts to increase its preservation service and product
offerings. General, administrative, and marketing expenses for the
fourth quarters of 2009 and 2008 included benefits of $165,000 and
$530,000, respectively, related to the adjustment of reserves for
product liability losses. General, administrative, and marketing
expenses for the full year of 2009 and 2008 included benefits of
$570,000 and $980,000, respectively, related to the adjustment of
reserves for product liability losses. The fourth quarter of 2009
also includes a charge of approximately $377,000 related to a
reduction in workforce. Research and development expenses were $1.4
million for each of the fourth quarters of 2009 and 2008. Research
and development expenses were $5.2 million and $5.3 million for the
full years of 2009 and 2008, respectively. Research and development
spending in 2009 was primarily focused on the Company's BioGlue and
related products and SynerGraft® tissues and products. As of
December 31, 2009, the Company had $35.1 million in cash, cash
equivalents, and restricted securities, compared to $22.8 million
at December 31, 2008. Of this $35.1 million, $2.6 million was
received from the U.S. Department of Defense as advance funding for
the development of BioFoam® protein hydrogel technology, and $5.0
million was designated as long-term restricted money market funds
due to a financial covenant requirement under the Company's credit
agreement. The Company has net operating loss carryforwards that
will reduce required cash payments for federal and state income
taxes for the 2010 tax year. 2010 Financial Guidance The Company
expects total revenues for the full year of 2010 to be between
$118.0 million and $123.0 million, which includes between $1.5
million and $2.5 million related to funding received from the
Department of Defense in connection with the development of
BioFoam. The Company expects tissue processing revenues and BioGlue
revenues to each increase between mid-single and low-double digits
on a percentage basis in 2010 compared to 2009, with HemoStase
revenues increasing significantly more than that on a percentage
basis. The Company expects earnings per share of between $0.36 and
$0.40 for 2010. Our earnings guidance contains general expenses
associated with business development opportunities, but does not
include significant expenses associated with specific targets, such
as Medafor or potential changes in the value of the Medafor-related
derivative. Depending upon our course of action and the ultimate
result of those actions, such as a proxy contest or the completion
of an acquisition, we could incur expenses or changes in the value
of the derivative that could materially affect our guidance.
Webcast and Conference Call Information The Company will hold a
teleconference call and live webcast today at 10:00 a.m. Eastern
Time to discuss the results followed by a question and answer
session hosted by Mr. Anderson. To listen to the live
teleconference, please dial 201-689-8261 a few minutes prior to
10:00 a.m. A replay of the teleconference will be available from
February 18 through February 28 and can be accessed by calling
877-660-6853 (toll free) or 201-612-7415. The account number for
the replay is 244 and the conference number is 343662. The live
webcast and replay can be accessed by going to the Investor
Relations section of the CryoLife Web site at
http://www.cryolife.com/ and selecting the heading Webcasts &
Presentations. About CryoLife, Inc. Founded in 1984, CryoLife, Inc.
is a leader in the processing and distribution of implantable
living human tissues for use in cardiac and vascular surgeries
throughout the U.S. and Canada. The Company's CryoValve® SG
pulmonary heart valve, processed using CryoLife's proprietary
SynerGraft® technology, has FDA 510(k) clearance for the
replacement of diseased, damaged, malformed, or malfunctioning
native or prosthetic pulmonary valves. The Company's CryoPatch® SG
pulmonary cardiac patch has FDA 510(k) clearance for the repair or
reconstruction of the right ventricular outflow tract (RVOT), which
is a surgery commonly performed in children with congenital heart
defects, such as tetralogy of Fallot, truncus arteriosus, and
pulmonary atresia. CryoPatch SG is distributed in three anatomic
configurations: pulmonary hemi-artery, pulmonary trunk, and
pulmonary branch. The Company's BioGlue® Surgical Adhesive is FDA
approved as an adjunct to sutures and staples for use in adult
patients in open surgical repair of large vessels. BioGlue is also
CE Marked in the European Community and approved in Canada and
Australia for use in soft tissue repair. The Company's BioFoam®
Surgical Matrix is CE Marked in the European Community for use as
an adjunct in the sealing of abdominal parenchymal tissues (liver
and spleen) when cessation of bleeding by ligature or other
conventional methods is ineffective or impractical. BIOGLUE
Aesthetic® Medical Adhesive is CE marked in the European Community
for periosteal fixation following endoscopic browplasty (brow lift)
in reconstructive plastic surgery and is distributed by a third
party for this indication. CryoLife distributes HemoStase® a
hemostatic agent, in much of the U.S. for use in cardiac and
vascular surgery and in many international markets for cardiac,
vascular, and general surgery, subject to certain exclusions.
Statements made in this press release that look forward in time or
that express management's beliefs, expectations or hopes are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements include
those regarding anticipated 2010 performance and statements
regarding the expected impact of our net operating loss
carryforwards on our cash outlays for tax obligations. These future
events may not occur as and when expected, if at all, and, together
with our business, are subject to various risks and uncertainties.
These risks and uncertainties include that we are significantly
dependent on our revenues from BioGlue and are subject to a variety
of risks affecting this product, we are subject to stringent
domestic and foreign regulation which may impede the approval
process of our tissues and products, hinder our development
activities and manufacturing processes and, in some cases, result
in the recall or seizure of previously cleared or approved tissues
and products, our proposed acquisition of Medafor poses a number of
risks, Medafor's management has rejected our acquisition offer and
refused to negotiate with us, and if we attempt to launch a hostile
offer to acquire Medafor we will incur significant expense and may
not succeed; in the event such a hostile offer does succeed, we
will not have the benefit of due diligence and may incur
unanticipated costs or liabilities, the lawsuit we filed against
Medafor regarding our distribution agreement with Medafor may
adversely impact our relationship with Medafor and could hinder our
distribution of HemoStase or prevent us from distributing
HemoStase, healthcare policy changes, including pending proposals
to reform the U.S. healthcare system, may have a material adverse
effect on us, uncertainties related to patents and protection of
proprietary technology may adversely affect the value of our
intellectual property, uncertainties related to patents and
protection of proprietary technology for products distributed by
CryoLife may adversely affect our ability to distribute those
products, the tissues we process and our products allegedly have
caused and may in the future cause injury to patients, and we have
been and may be exposed to product liability claims and additional
regulatory scrutiny as a result, we are dependent on the
availability of sufficient quantities of tissue from human donors,
our CryoValve SGPV post-clearance study may not provide expected
results, demand for our tissues and products could decrease in the
future, which could have a material adverse effect on our business,
the success of many of our tissues and products depends upon strong
relationships with physicians, consolidation in the health care
industry could lead to demands for price concessions or limits or
eliminate our ability to sell to certain of our significant market
segments, our existing insurance policies may not be sufficient to
cover our actual claims liability, we may be unable to obtain
adequate insurance at a reasonable cost, if at all, the loss of any
of our sole-source suppliers could have an adverse effect on our
revenues, financial condition, profitability, and cash flows,
intense competition may affect our ability to operate profitably,
regulatory action outside of the U.S. has affected our business in
the past and may affect our business in the future, rapid
technological change could cause our services and products to
become obsolete, continued fluctuation of foreign currencies
relative to the U.S. dollar could materially and adversely impact
our business, our credit facility limits our ability to pursue
significant acquisitions, key growth strategies may not generate
the anticipated benefits, there are limitations on the use of our
net operating loss carryforwards, our ability to borrow under our
credit facility may be limited, we may not be successful in
obtaining necessary clinical results and regulatory approvals for
services and products in development, and our new services and
products may not achieve market acceptance, extensive government
regulation may adversely affect our ability to develop and market
services and products, investments in new technologies and
acquisitions of products or distribution rights may not be
successful, if we are not successful in expanding our business
activities in international markets, we may be unable to increase
our revenues, we are not insured against all potential losses, and
natural disasters or other catastrophes could adversely affect our
business, financial condition, and profitability, and we are
dependent on key personnel. These risks and uncertainties include
the risk factors detailed in our Securities and Exchange Commission
filings, including our Form 10-Q filing for the quarter ended March
31, 2009, our Form 10-Q filing for the quarter ended June 30, 2009,
our Form 10-Q filing for the quarter ended September 30, 2009, our
Form 10-K to be filed for the year ended December 31, 2009 and the
Company's other SEC filings. The Company does not undertake to
update its forward-looking statements. CRYOLIFE, INC. AND
SUBSIDIARIES Financial Highlights (In thousands, except per share
data) Three Months Twelve Months Ended Ended December 31, December
31, --------------- --------------- 2009 2008 2009 2008
--------------- --------------- (Unaudited) (Audited) Revenues:
Preservation services $13,784 $12,319 $56,456 $53,656 Products
14,493 12,994 54,162 50,493 Other 338 219 1,067 910 ---------------
--------------- Total revenues 28,615 25,532 111,685 105,059
--------------- --------------- Cost of preservation services and
products: Preservation services 8,346 6,730 32,767 29,112 Products
2,672 2,293 9,150 8,153 --------------- --------------- Total cost
of preservation services and products 11,018 9,023 41,917 37,265
--------------- --------------- Gross margin 17,597 16,509 69,798
67,794 --------------- --------------- Operating expenses: General,
administrative, and marketing 12,585 12,334 50,025 48,831 Research
and development 1,393 1,371 5,247 5,309 ---------------
--------------- Total operating expenses 13,978 13,705 55,272
54,140 --------------- --------------- Operating income 3,619 2,804
14,496 13,654 --------------- --------------- Interest expense (85)
62 83 263 Interest income (3) (96) (76) (381) Change in valuation
of derivative (24) -- (24) -- Other expense, net 59 121 159 236
--------------- --------------- Income before income taxes 3,672
2,717 14,354 13,536 Income tax expense (benefit) 1,306 (19,024)
5,675 (18,414) --------------- --------------- Net income $2,366
21,741 8,679 $31,950 =============== =============== Income per
common share: Basic $0.08 $0.78 $0.31 $1.15 ===============
=============== Diluted $0.08 $0.76 $0.31 $1.13 ===============
=============== Weighted average common shares outstanding: Basic
28,202 27,983 28,106 27,800 Diluted 28,473 28,478 28,310 28,351
CRYOLIFE, INC. AND SUBSIDIARIES Financial Highlights (In thousands)
Three Months Ended Twelve Months Ended December 31, December 31,
-------------------- --------------------- 2009 2008 2009 2008
-------------------- --------------------- (Unaudited) (Audited)
Preservation services: Cardiac tissue $6,697 $5,894 $26,074 $25,514
Vascular tissue 7,054 6,362 30,201 27,417 Orthopaedic tissue 33 63
181 725 -------------------- --------------------- Total
preservation services 13,784 12,319 56,456 53,656
-------------------- --------------------- Products: BioGlue and
related products 12,583 12,088 47,906 48,570 HemoStase 1,869 806
6,008 1,532 Other medical devices 41 100 248 391
-------------------- --------------------- Total products 14,493
12,994 54,162 50,493 -------------------- ---------------------
Other 338 219 1,067 910 -------------------- ---------------------
Total revenues $28,615 $25,532 $111,685 $105,059
==================== ===================== Revenues: U.S. $23,830
$21,547 $94,094 $89,297 International 4,785 3,985 17,591 15,762
-------------------- --------------------- Total revenues $28,615
$25,532 $111,685 $105,059 ====================
===================== December 31, December 31, 2009 2008
------------- ------------ (Audited) (Audited) Cash and cash
equivalents and restricted securities $30,121 $17,763 Receivables,
net 14,636 13,999 Deferred preservation costs 36,445 34,913
Inventories 6,446 7,077 Investment in equity securities 3,221 --
Restricted money market funds, long-term 5,000 5,000 Total assets
133,859 125,037 Shareholders' equity 110,446 98,368 CRYOLIFE, INC.
AND SUBSIDIARIES Unaudited Reconciliation of Non-GAAP Net Income
and Diluted Income per Common Share (In thousands, except per share
data) Three Months Ended Twelve Months Ended December 31, December
31, ------------------- -------------------- 2009 2008 2009 2008
------------------- -------------------- GAAP: Income before income
taxes $3,672 $2,717 $14,354 $13,536 Income tax expense 1,306
(19,024) 5,675 (18,414) ------------------- --------------------
Net income 2,366 $21,741 $8,679 $31,950 ===================
==================== Diluted Income per common share $0.08 $0.76
$0.31 $1.13 =================== ==================== Weighted
average common shares outstanding, diluted 28,473 28,478 28,310
28,351 Reconciliation excluding items: Net Income, GAAP $2,366
$21,741 $8,679 $31,950 Non-GAAP adjustments to net income: Charge
for reduction in workforce (a) 377 -- 377 -- Adjustment to income
taxes (b) (136) (20,002) (151) (23,828) -------------------
-------------------- Net adjustment to net income 241 (20,002) 226
(23,828) Net income, non-GAAP $2,607 $1,739 $8,905 $8,122
=================== ==================== Diluted Income per common
share, GAAP $0.08 $0.76 $0.31 $1.13 Non-GAAP adjustments to Diluted
Income per common share: Charge for reduction in workforce (a) 0.01
-- 0.01 -- Adjustment to income taxes (b) 0.00 (0.70) 0.00 (0.84)
------------------- -------------------- Net adjustment to net
income 0.01 (0.70) 0.01 (0.84) Diluted Income per common share,
non-GAAP $0.09 $0.06 $0.32 $0.29 ===================
==================== Investors should consider this non-GAAP
information in addition to, and not as a substitute for, financial
measures prepared in accordance with U.S. GAAP. In addition, this
non-GAAP financial information may not be the same as similar
measures presented by other companies. a - Charge for reduction in
force reflects expense recorded in the 2009 periods related to the
Company's reduction in force. There was no corresponding charge in
the 2008 periods. The Company believes that this disclosure
provides useful information for investors to evaluate the Company's
results excluding these charges. b - For the three and twelve
months ended December 31, 2009 the adjustment for income tax is the
tax benefit on the charge for reduction in workforce at a rate of
36% for the three months and 40% for the twelve months. For the
three and twelve months ended December 31, 2008 the adjustment for
income tax includes the reversal of the tax benefit recorded of
$19.0 million and $18.4 million, respectively, and tax expense on
income before taxes of $2.7 million and $13.5 million,
respectively, at a rate of 36% for the three months and 40% for the
twelve months. The Company believes that this disclosure provides
useful information for investors to evaluate the Company's results
excluding changes due to fluctuations in the Company's income tax
rate. For additional information about the company, visit
CryoLife's Web site: http://www.cryolife.com/. Media Contacts: D.
Ashley Lee Executive Vice President, Chief Financial Officer and
Chief Operating Officer Phone: 770-419-3355 Nina Devlin Edelman
Phone: 212-704-8145 DATASOURCE: CryoLife, Inc. CONTACT: Media: D.
Ashley Lee, Executive Vice President, Chief Financial Officer and
Chief Operating Officer of CryoLife, +1-770-419-3355; or Nina
Devlin of Edelman, +1-212-704-8145 Web Site:
http://www.cryolife.com/
Copyright
CryoLife (NYSE:CRY)
Historical Stock Chart
From May 2024 to Jun 2024
CryoLife (NYSE:CRY)
Historical Stock Chart
From Jun 2023 to Jun 2024